EGFR TKI (1st generation) · small molecule
erlotinib
10 active trials across 10 of our biomarkers, targeting EGFR. 6 active approvals for a biomarker on marked.bio.
Also known as OSI-774, Tarceva.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Approvals and pivotal results
Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.
| Therapy | Biomarker | Tumour | United States | European Union |
|---|---|---|---|---|
erlotinib
|
EGFR exon 19 deletion / L858R | NSCLC | Approved 2013 | Approved 2011 |
In the US label
EURTAC
vs platinum-based chemotherapy, 86 vs 88 patients Stopped for side effects 14% Trial details and side effects
In the EU product information
EURTAC
vs platinum-based chemotherapy, 86 vs 87 patients Trial details and side effects
In the EU product information
SATURN
vs placebo, 49 (EGFR-mutated subgroup of 889) Trial details and side effects
|
||||
ramucirumab with erlotinib
|
EGFR exon 19 deletion / L858R | NSCLC | Approved 2020 | Approved 2020 |
RELAY
vs placebo + erlotinib, 224 vs 225 patients Stopped for side effects 13% (all study drugs) Trial details and side effects
|
||||
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 7 | 112 | Phase 3 |
| KRAS G12C | 3 | 9 | Phase 3 |
| ALK fusion | 2 | 8 | Phase 3 |
| KRAS G12D | 2 | 7 | Phase 3 |
| BRAF V600E | 1 | 3 | Phase 2 |
| HER2 (ERBB2) activating mutation | 1 | 1 | Phase 2 |
| RET fusion or mutation | 1 | 1 | Phase 2 |
| EGFR exon 20 insertion | 0 | 2 | – |
| PIK3CA activating mutation | 0 | 1 | – |
| ROS1 fusion | 0 | 1 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of erlotinib.
- Eli Lilly 2
- OBI Pharma 1
- AbbVie 1
- Roche 1
Trials
10 of 121 trials shown
-
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
ramucirumab FDA EUerlotinib FDA EUgefitinib FDA EUosimertinib FDA EU
…h erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\].
EGFR exon 19 deletion / L858RMetastatic Non-Small Cell Lung Cancer
-
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
erlotinib FDA EU
Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation
EGFR exon 19 deletion / L858RALK fusionLung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
-
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
KRAS G12CKRAS G12DNon Small Cell Lung Cancer
-
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
gefitinib FDA EUerlotinib FDA EUafatinib FDA EUosimertinib FDA EU
Positive EGFR mutations are diagenesis.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
-
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
30 μg OBI-833/100 μg OBI-821erlotinib FDA EU
The tumor harbors an exon 19 deletion or exon 21 L858R mutation in EGFR, confirmed locally.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
cabozantiniberlotinib FDA EU
Tumor with a sensitizing mutation in epidermal growth factor receptor (EGFR), defined as follows:
EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DBRAF V600EHER2 (ERBB2) activating mutationRET fusion or mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
-
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
erlotinib FDA EUhydroxychloroquine
An EGFR sensitizing mutation must be detected in tumor tissue.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
divarasibatezolizumabcetuximabbevacizumaberlotinibGDC-1971inavolisib
Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
KRAS G12CNon-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
osimertinib FDA EUnivolumabtelisotuzumab vedotinerlotinib FDA EU
…ced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resi…
EGFR exon 19 deletion / L858RAdvanced Solid Tumors Cancer
-
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
carboplatincisplatincrizotinib FDA EUerlotinibgemcitabinenivolumabpaclitaxelpembrolizumabpemetrexed
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD-1/PD-L1/CTLA-4
ALK fusionStage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
-
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Elemene plus first or third generation EGFR-TKIsgefitinib FDA EUerlotinib FDA EUicotinibosimertinib FDA EUaumolertinibfurmonertinib
Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefit…
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
-
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
erlotinib FDA EUgefitinib FDA EUicotinibdocetaxelpemetrexedcisplatincarboplatin
EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21);
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
-
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
erlotinib FDA EU
Non-small cell lung cancer with an EGFR activating mutation
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
erlotinib FDA EU
Locally advanced or metastatic (stage III/IV) non-small cell lung cancer with EGFR mutations
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
erlotinib FDA EU
Positive EGFR mutation tested in certified lab (although EGFR test is not mandatory only if available).
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer Metastatic
-
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
nazartiniberlotinib FDA EUgefitinib FDA EU
…ic, stage IIIB/ IIIC or stage IV NSCLC with documented EGFR activating mutation (L858R or ex19del)
EGFR exon 19 deletion / L858RCarcinoma, Non-small Cell Lung
-
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
AZD3759erlotinib FDA EUgefitinib FDA EU
Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
-
Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC
erlotinib FDA EU
EGFR activating mutations in exon 18, 19 or 21were detected in tumor tissue or plasma.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, Epidermal Growth Factor Receptor
-
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
naquotinib mesilateerlotinib FDA EUgefitinib FDA EU
Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examina…
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC)
-
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
pemetrexedcisplatinerlotinib FDA EUvinorelbine
Confirmed with Exon 19 deletion or L858R EGFR mutation
EGFR exon 19 deletion / L858RNSCLC
-
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
erlotinib FDA EUbevacizumab
Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, suc…
EGFR exon 19 deletion / L858RNon-squamous Non-small Cell Lung Cancer
-
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
gefitinib FDA EUerlotinib FDA EUicotinib
Positive EGFR mutation.
EGFR exon 19 deletion / L858RStage IV EGFR Mutated NSCL With Brain Metastases
-
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
gefitinib FDA EUerlotinib FDA EUicotinib
… who was confirmed non-small cell lung cancer (NSCLC) by histology or cytology, harboring EGFR mutant type (19 and/or 21 exon mutation).
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
erlotinib FDA EUCHEMOTHERAPY ONLY
Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or L858R, G719X or L861Q)
EGFR exon 19 deletion / L858RNSCLC Patients With EGFR Activating Mutation
-
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
osimertinib FDA EUerlotinib FDA EUgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).
EGFR exon 19 deletion / L858RLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
-
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
rociletiniberlotinib FDA EU
Documented evidence of a tumor with activating EGFR mutations by local testing.
EGFR exon 19 deletion / L858REGFR exon 20 insertionNon-Small Cell Lung Cancer
-
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
erlotinib FDA EU
Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection methods:ARMS-PCR, sequence method)
EGFR exon 19 deletion / L858RNSCLC, EGFR Mutation
-
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
gemcitabinecisplatincarboplatinerlotinib FDA EU
…hemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
erlotinib FDA EUonartuzumab
…MET-Positive Unresectable Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
erlotinib FDA EUgemcitabinecisplatin
EGFR activating mutation in exon 19 or 21 by the biopsy of primary tumor or N2 lymph node.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
erlotinib FDA EUChemotherapy
Presence of epidermal growth factor receptor (EGFR) mutations in tumours.
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
erlotinib FDA EUgefitinib FDA EU
EGFR mutation (exon 19 or 21)
EGFR exon 19 deletion / L858RLung Cancer
-
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
erlotinib FDA EUgemcitabinecarboplatin
EGFR exon19 deletions or exon 21 L858R mutation by the DNA direct PCR sequencing using fresh tumor sample or p…
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
aumolertiniberlotinib FDA EUcisplatincarboplatinpemetrexed
… samples are confirmed as EGFR sensitive mutations by central laboratory tests (including Ex19del or L858R, both alone or with other EGFR mutations).
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer Stage IIIA
-
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
LY3499446abemaciclibcetuximaberlotinibdocetaxel
Participants must have diagnosis of a solid tumor with KRAS G12C mutation that did not respond to at least 1 line of standard therapy and has spread to ot…
KRAS G12CAdvanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
-
Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
bevacizumaberlotinib FDA EU
A tumor harboring an EGFR mutation known to be associated with erlotinib sensitivity (exon 19 deletion and L858R)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, Brain Neoplasms
-
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
trametiniberlotinib FDA EU
Somatic activating mutation in EGFR Radiographic progression during treatment with erlotinib.
EGFR exon 19 deletion / L858RLung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
-
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
erlotinib FDA EUbevacizumab
Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)
EGFR exon 19 deletion / L858REGFR Positive Non-small Cell Lung Cancer
-
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
gefitinib FDA EUerlotinib FDA EUicotinib
…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain …
EGFR exon 19 deletion / L858RLung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer
-
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
gefitinib FDA EUerlotinib FDA EUicotinibThymosin Alpha 1
…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and showed stable disease after 3 months TKI, evaluated twice by PET/CT scan, brain MRI…
EGFR exon 19 deletion / L858RLung Adenocarcinoma
-
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
erlotinib FDA EUOnalespib Lactate
…, histologically confirmed NSCLC that harbors an EGFR activating mutation (exon 21 L858R, exon 19 deletion, exon 18 G719X, exon 21 L861Q) with progressive disease by RECIST 1.1 on a previous EGFR-…
EGFR exon 19 deletion / L858REGFR exon 20 insertionRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
-
Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
lung adenocarcinoma proved by histology;with mutant EGFR;ECOG PS 0-2;Clinical stage IIIb or IV;without other fatal disease;without hemorrhagic dis…
EGFR exon 19 deletion / L858RLung Cancer
-
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
erlotinib FDA EU
…ants must possess at least two of the following clinical characteristics which enrich for EGFR mutations:
EGFR exon 19 deletion / L858REpidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
-
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Thymalfasin (Thymosin alpha 1, Ta1)afatinib FDA EUgefitinib FDA EUerlotinib FDA EU
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
EGFR exon 19 deletion / L858REGFR Mutation Positive Non Small Cell Lung Cancer
-
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
gilteritiniberlotinib FDA EU
Participant had a documented exon 19 deletion or exon 21 L858R EGFR activating mutation.
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
-
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
erlotinib FDA EUBemcentinib
Participants who have an activating EGFR mutation may have up to 4 lines of previous treatment in the advanced setting.
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
buparlisiberlotinib FDA EU
Exon 19 deletion
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Ficlatuzumaberlotinib FDA EU
An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation
erlotinib FDA EUpaclitaxelcarboplatin
Low abundant activating EGFR mutation: EGFR exon 19 deletion or exon 21 L858R, which are positive by real-time PCR methods and negative by standard se…
EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
-
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
erlotinib FDA EUcisplatincarboplatindocetaxelpaclitaxelpemetrexed
L858R
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Itacitiniberlotinib FDA EU
Documented evidence of an activating mutation in EGFR in tumor samples (exon 19 deletions or point mutation L858R in exon 21 or point mutations at codon 719).
EGFR exon 19 deletion / L858RSolid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
-
Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
erlotinib FDA EU
Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.
EGFR exon 19 deletion / L858RLung, Carcinoma
-
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
pemetrexedcarboplatincisplatinerlotinib FDA EU
Histologically- or cytologically-confirmed Stage IV NSCLC with an EGFR exon-19 deletion or L858R mutation
EGFR exon 19 deletion / L858RRecurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
-
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
gemcitabineerlotinib FDA EU
EGFR sensitive mutations, such as exon 19 del, or exon 21 L858R
EGFR exon 19 deletion / L858RCarcinoma, Non-Small Cell Lung, EGFR Gene Mutation
-
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
Foretiniberlotinib FDA EU
…the following: Evidence of Epidermal growth factor receptor activating mutation positive (EGFRm) or Epidermal growth factor receptor (EGFR)/ Wild Type (WT) genes in Deoxyribonucleic aci…
EGFR exon 19 deletion / L858RROS1 fusionCancer
-
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
erlotinib FDA EU
Histological or cytologic diagnosis of stage IV lung adenocarcinoma and confirmed EGFR mutation
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
trastuzumabpertuzumaberlotinibvemurafenib FDA EUcobimetinib FDA EUVismodegibalectinibatezolizumab FDA
…esting results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing r…
BRAF V600EALK fusionNeoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
-
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
carboplatincisplatincrizotiniberlotinib FDA EUetoposidepaclitaxel
…ensitive" mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement
EGFR exon 19 deletion / L858RALK fusionStage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
-
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
LY2875358erlotinib FDA EU
…known to be associated with EGFR tyrosine kinase inhibitor (TKI) drug sensitivity (G719X, exon 19 deletion, L858R, L861Q)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
cabozantiniberlotinib FDA EU
…st have histologically or cytologically confirmed non-small cell lung cancer harboring an EGFR mutation
EGFR exon 19 deletion / L858RRecurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
-
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
erlotinib FDA EUgefitinib FDA EU
Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation.
EGFR exon 19 deletion / L858RAdvanced Stage Non Small Cell Lung Cancer
-
Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
erlotinib FDA EU
Activating mutation in EGFR
EGFR exon 19 deletion / L858RStage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
-
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
erlotinib FDA EU
Neither with EGFR mutation nor c-met expression on Ventana Benchmark instrument(Met negative expression definition: …
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
afatinib FDA EUerlotinib FDA EU
Patients with stage IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who were previously responsive to one line of EGFR tyrosine ki…
EGFR exon 19 deletion / L858RLung Cancer
-
Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
docetaxelpemetrexederlotinib FDA EU
…avorable surgical locally advanced stage (stage IIIB) or metastatic NSCLC (IV), Sensitive EGFR gene mutation
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Documented ALK rearrangement based on Food and Drug Administration (FDA)-approved test
ALK fusionNon-Small-Cell Lung Carcinoma
-
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
erlotinib FDA EUdocetaxel
Tumor specimen with EGFR gene mutation of exon 19 deletion and L858R, G719X, L861Q mutation
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer(NSCLC)
-
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
erlotinib FDA EUbevacizumab
Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)
EGFR exon 19 deletion / L858RLung Cancer
-
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
erlotinib FDA EUcisplatinvinorelbine
… 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution;
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer Stage III
-
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
bevacizumaberlotinib FDA EU
…ology with activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R mutation)
EGFR exon 19 deletion / L858REGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
-
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
erlotinib FDA EU
only those patients who have a mutation of the EGFR tyrosine kinase domain will be able to enroll in this study.
EGFR exon 19 deletion / L858RMalignant Peritoneal Mesothelioma
-
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
gefitinib FDA EUfulvestranterlotinib FDA EU
The presence of analysable tissue for the research of EGFR activating mutation.
EGFR exon 19 deletion / L858RStage IV Lung Cancer
-
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
erlotinib FDA EU
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
EGFR exon 19 deletion / L858RNSCLC Stage II, NSCLC, Stage IIIA
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
erlotinib FDA EU
…Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
erlotinib FDA EU
Patients in initial treatment should be detected EGFR mutation;
EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer, Brain Metastases
-
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
erlotinib FDA EU
Histologically or cytologically confirmed stge IV EGFR-mutant NSCLC
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
erlotinib FDA EU
The biopsy specimen shows EGFR mutation in exon 19 or 21 by DNA sequencing.
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
OSI-906erlotinib FDA EU
Exon 19 deletion or exon 21 activating mutation in EGFR
EGFR exon 19 deletion / L858RNSCLC, Non Small Cell Lung Cancer
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
erlotinib FDA EU
Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
erlotinib FDA EUHsp90 inhibitor AUY922mutation analysis
…or an investigational EGFR TK inhibitor OR a documented mutation in the EGFR gene (G719X, exon 19 deletion, L858R, L861Q)
EGFR exon 19 deletion / L858RAdenocarcinoma of the Lung, Non-small Cell Lung Cancer
-
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
erlotinib FDA EUvinorelbinecisplatin
EGFR activating mutation in exon 19 or 21 and KARS
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer Stage IIIA
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
erlotinib FDA EU
Locally advanced or metastatic NSCLC with EGFR mutations
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
erlotinib FDA EU
…atment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
EGFR exon 19 deletion / L858RCarcinoma，Non-Small-Cell Lung
-
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
erlotinib FDA EU
…Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
NOTE: a patient with an EGFR activating mutation who has received EGFR-TKI therapy as first line therapy, but has not received platinum-ba…
EGFR exon 19 deletion / L858RAdenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma
-
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
erlotinib FDA EU
Presence of epidermal growth factor receptor (EGFR) mutations
EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer
-
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
erlotinibpemetrexeddocetaxelgemcitabine
…rlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
KRAS G12CKRAS G12DMetastatic Non-Small Cell Lung Cancer
-
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
erlotinib FDA EU
…ancer, confirmed at MSKCC EGFR sensitizing mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be documented in the primary or recurrent tumor
EGFR exon 19 deletion / L858RLung Cancer
-
Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
erlotinib FDA EU
… Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
erlotinib FDA EU
Tumor EGFR mutation
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
erlotinib FDA EUdocetaxelcisplatin
…Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
EGFR exon 19 deletion / L858RNeoplasms, Lung, Carcinoma, Non-Small Cell Lung, Drug Therapy, Genes, EGFR
-
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
…all Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
KRAS G12CKRAS G12DNon Small Cell Lung Carcinoma
-
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
erlotinib FDA EU
Presence of exon 19 or exon 21 EGFR activating mutation.
EGFR exon 19 deletion / L858RLung Cancer
-
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
erlotinib FDA EU
A patients with EGFR mutation (including exon 19 deletion, L858R)
EGFR exon 19 deletion / L858RLeptomeningeal Carcinomatosis, Non-small Cell Lung Cancer
-
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
erlotinib FDA EU
…tations characterized by in-frame deletions (747-750), and Exon 21 mutations resulting in L858R substitutions).
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
A documented mutation in EGFR exons 19 or 21.
EGFR exon 19 deletion / L858RLung Adenocarcinoma
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
erlotinib FDA EU
Tumor samples must have either exon 19 deletion mutations or the exon 21 L858R point mutation
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
erlotinib FDA EUpemetrexedcisplatin
Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R, L861Q)
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer, Lung Cancer
-
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
erlotinib FDA EU
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
EGFR exon 19 deletion / L858RLung Neoplasms, Non-Small Cell Lung Cancer, Adenocarcinoma, Bronchiolo-Alveolar
-
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
erlotinib FDA EU
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
EGFR exon 19 deletion / L858RMetastatic Pancreatic Cancer
-
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
gefitinib FDA EUerlotinib FDA EUafatinib FDA EUosimertinib FDA EU
EGFR sensitizing mutation must be detected in tumor tissue.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
capmatiniberlotinib FDA EU
EGFR mutation (L858R and /or ex19del)
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
gefitinib FDA EUerlotinib FDA EU
Newly diagnosed or patients on treatment for histologically confirmed advanced EGFR-mutant NSCLC defined as unresectable stage 3A, stage 3B or stage 4.
EGFR exon 19 deletion / L858RLung Cancer
-
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
Pacritiniberlotinib FDA EU
…ogically confirmed metastatic or unresectable locally advanced NSCLC with known sensitive EGFR mutations.
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
-
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Momelotinib (MMB)erlotinib FDA EU
Metastatic NSCLC with documented EGFR exon 19 deletion or exon 21 (L858R) substitution mutation
EGFR exon 19 deletion / L858REGFR Mutated EGFR TKI Naive Metastatic NSCLC
-
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
erlotinib FDA EU
…CER: trial eligibility will be restricted to those participants whose tumors harbor known EGFR activating mutations
EGFR exon 19 deletion / L858RHIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
-
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
alectinibatezolizumaberlotinib FDA EU
Participants in Stage 2 (Expansion) receiving erlotinib: i) sensitizing mutation in the EGFR gene and ii) consent to collection of tumor tissue samples before, during, and after trea…
EGFR exon 19 deletion / L858RALK fusionNon-Small Cell Lung Cancer
-
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
capmatiniberlotinib FDA EU
G719X, exon 19 deletion, L858R, L861Q)
EGFR exon 19 deletion / L858RRecurrent Non-small Cell Lung Cancer
-
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
erlotinib FDA EU
Documented presence of EGFR mutation confirmed by MSKCC or a local facility.
EGFR exon 19 deletion / L858REGFR-Mutant Lung Cancer
-
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
binimetiniberlotinib FDA EU
Have a tissue or blood proven KRAS or EGFR mutation confirmed in a Clinical Laboratory Improvement Amendments (CLIA)certified lab (only requi…
EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DLung Cancer, Non-Small Cell Lung Cancer
-
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
ipilimumaberlotinib FDA EUcrizotinibnivolumab
Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated.
EGFR exon 19 deletion / L858RALK fusionNon-small Cell Lung Cancer
-
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
erlotinib FDA EUPralatrexate
Have an epidermal growth factor receptor (EGFR)-sensitive mutation (as G719C in exon 18, E746-A750 in exon 90, L858R in exon 21) and have been previously treated with EGFR inhibitor therap…
EGFR exon 19 deletion / L858RAdvanced Cancers, Solid Tumors
-
A Study of LY2875358 in Japanese Participants With Advanced Cancer
LY2875358erlotinib FDA EUgefitinib FDA EU
…istologic or cytologic diagnosis of advanced NSCLC with epidermal growth factor receptor (EGFR) activating mutation, Stage IV per the 7th edition of the AJCC Staging Criteria for NSCLC.
EGFR exon 19 deletion / L858RSolid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
-
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
erlotinib FDA EU
…n Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
EGFR exon 19 deletion / L858RBrain Cancer
-
Erlotinib and Temsirolimus for Solid Tumors
erlotinib FDA EUTemsirolimus
…sion Phase ONLY): Patients must have tumor harboring PTEN loss, PIK3CA mutation, , and/or EGFR mutation.
EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DBRAF V600EPIK3CA activating mutationSolid Tumors
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
…ional status may be determined either by polymerase chain reaction (PCR) assay (e.g., DxS KRAS mutation kit) or by direct sequencing of KRAS exon 2, codons 12 and 13
KRAS G12CKRAS G12DAdenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
-
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
erlotinib FDA EUcrizotinib
Patients with tumors that harbor either EGFR sensitizing mutations or ALK rearrangement.
EGFR exon 19 deletion / L858RALK fusionNon-Small Cell Lung Cancer
-
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
anlotinibgefitinib FDA EUerlotinib FDA EUicotinib
The patients should be confirmed with EGFR mutation \[e.g., T 790 M , exon 19 deletion, L 858 R, etc\],
EGFR exon 19 deletion / L858RNSCLC
-
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma
metforminerlotinib FDA EUafatinib FDA EUgefitinib FDA EU
NSCLC EGFR mutation-positive
EGFR exon 19 deletion / L858RNon-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation
-
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
erlotinib FDA EU
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
EGFR exon 19 deletion / L858ROligometastatic Lung Adenocarcinoma
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
gefitinib FDA EUerlotinib FDA EUafatinib FDA EU
Patients with tumors harboring EGFR mutation (del 19 or L858R mutation) 6.
EGFR exon 19 deletion / L858REGFR Mutation Positive Non-small Cell Lung Cancer
No trials match these filters.